Enoxaparin News
New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Sanofi-aventis announced today that one year findings from the landmark ExTRACT-TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients with acute ST-segment elevation yocardial infarction (STEMI) for...
Delay for Momenta's generic version of Lovenox cheers Sanofi
Less than a fortnight after winning a famous patent victory that protects Plavix, Sanofi-Aventis has received a fresh boost with the news that a generic version of its biggest earner, the blood thinner Lovenox, will not be...
The Lancet Publishes PREVAIL Study Results
Showing Lovenox® Superiority Over Unfractionated Heparin For Reducing The Risk Of Venous Thromboembolism In Patients With Acute Ischemic Stroke.
Teva wins Lovenox patent case
A US District Court in California cancelled Sanofi-Aventis’s patent to Lovenox, which was originally due to expire in 2012.
Sanofi-Aventis loses US patent lawsuit on Lovenox
Sanofi-Aventis has suffered a major blow in the USA with the news that a California court has invalidated the patent on its top-selling antithrombotic Lovenox, an announcement which has sent its shares down 2% in early-morning...